Navigation Links
MacuCLEAR, Inc. to Present at OneMedForum New York 2011 and at the 2011 BIO Business Forum During the Annual BIO International Convention in Washington, D.C.
Date:6/16/2011

PLANO, Texas, June 16, 2011 /PRNewswire/ -- MacuCLEAR, Inc., a specialty clinical stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today that Philip G. Ralston, president and CEO, will be presenting at OneMedForum New York 2011 on Thursday, June 23, 2011 at 11:30 a.m. EDT at The Roosevelt Hotel in New York City.  

OneMedForum will focus on critical success factors for building companies internationally.  In addition to presentations by more than 70 emerging medical technology companies, delegates will gain insights in the critical areas of regulatory approval, reimbursement and distribution and sales organizations in the EU and U.S.

Concurrently, Mr. Ralston will also present at the 2011 BIO Business Forum during the annual BIO International Convention at the Walter E. Washington Convention Center in Washington, D.C.  Mr. Ralston's presentation will be given on Wednesday, June 29, 2011 at 9:15 a.m. EDT in the Adams Morgan Room.  The presentation will include an overview of the company with emphasis on the lead proprietary compound, MC-1101, which is being developed for the treatment of the dry form of age-related macular degeneration (AMD).

The BIO Business Forum is a unique platform for biotechnology and pharmaceutical companies, academic research institutions and investors from around the world to gather and discuss strategic opportunities.  This forum is featured within the BIO International Convention, the largest global event for the biotechnology industry, offering networking and partnering opportunities with policymakers, scientists, CEOs and newsmakers and hundreds of sessions covering biotech trends, policy issues and technological innovations.

About MacuCLEAR, Inc.

MacuCLEAR, Inc. is a clinical-stage specialty pharmaceutical company focused on developing innovative treatments for vascular and retinal diseases of the eye.  Its lead compound MC-1101 is a novel, topically delivered eye drop drug for treating and stopping the progression of age-related macular degeneration (AMD) from the early-stage (Dry AMD) to the late-stage (Wet AMD) by improving ocular blood flow.

The active ingredient of MC-1101 has been previously approved by the FDA as an oral antihypertensive drug.  MC-1101 has been granted 505 (b) 2 status and has formal Fast Track designation by the FDA.  In addition to MC-1101, MacuCLEAR's portfolio includes 11 compounds that are being developed for diabetic retinopathy, second-generation treatment for AMD and other vascular diseases of the eye.

George C.Y. Chiou, Ph.D., who led the development of Timolol, a pioneering treatment for glaucoma, invented this technology at Texas A&M University.

Founded in 2006, MacuCLEAR is a privately held Plano, TX-based company.  For additional information, please visit www.macuclear.com.

About Age-Related Macular Degeneration

AMD is the leading cause for blindness in the world in people 50 and older.  Dry AMD afflicts 90 percent of AMD sufferers and currently has no approved drug treatments.  

Media Contact:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach, amielach@tiberend.com
or
Claire Sojda, csojda@tiberend.com


'/>"/>
SOURCE MacuCLEAR, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use
2. NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society
3. Dendreon Announces Webcast Presentation at NASDAQ OMX 26th Investor Program
4. NeoStem to Present at Two Investor Events This Month
5. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
6. Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings
7. PAREXEL International to Present at Wells Fargo Healthcare Conference
8. Spherix to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
9. Sono-Tek to Present Scientific Paper on Food Safety at the IFT, as E. Coli Outbreak Affects Europes Food Supply
10. Masimo to Present at William Blair & Company 31st Annual Growth Stock Conference
11. IDEXX Laboratories to Present at William Blair 31st Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Weeks after hosting a carpal tunnel syndrome ... Fitzmaurice, hand surgeon and founder of the Fitzmaurice Hand Institute, has announced the addition ... is a state-of-the-art technology and only 1 of about 3 currently available in the ...
(Date:5/27/2016)... Jersey and READING, ... -- Indegene ( http://www.indegene.com ), ... marketingorientierten Lösungen für die Life-Science-Branche, Pharmaunternehmen und ... bekannter weltweiter Anbieter von innovativen wissenschaftlichen Support-Services ... des Starts von IntraScience heute den Ausbau ...
(Date:5/26/2016)... ISELIN, New Jersey and ... -- Indegene ( http://www.indegene.com ), a ... solutions to life science, pharmaceutical and healthcare organisations ... provider of innovative scientific support throughout the product ... alliance with the launch of IntraScience. ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments in ... the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient ... this year following FDA approval of a second application for a single patient, ...
Breaking Biology Technology:
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/10/2016)...   Unisys Corporation (NYSE: UIS ) today ... is testing its biometric identity solution at the Otay Mesa ... help identify certain non-U.S. citizens leaving the country. ... help determine the efficiency and accuracy of using biometric technologies ... run until May 2016. --> the United ...
Breaking Biology News(10 mins):